Stock Track | Sino Biopharm Shares Plunge After Major Licensing Deal

Stock Track10-08

Shares of Sino Biopharmaceutical Ltd. plummeted over 10% in Hong Kong trading on Monday morning, after the Chinese drug maker announced a major licensing agreement that will require significant upfront payments.

Sino Biopharm said one of its subsidiaries has signed an exclusive deal with YZY Biopharma to develop and commercialize the drug candidate M701 in mainland China. Under the terms of the deal, Sino Biopharm will pay around RMB315 million ($44 million) upfront to YZY.

The company could also be on the hook for up to RMB700 million ($98 million) in additional milestone payments tied to future sales of the drug. Investors appeared to view the substantial upfront cash commitment as weighing on Sino Biopharm's near-term finances, sparking the sharp sell-off in the stock on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187588565?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 17:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187588565","market":"us","top_or_hot":-1,"title":"Stock Track | Sino Biopharm Shares Plunge After Major Licensing Deal","media":"Stock Track","content":"<p>Shares of Sino Biopharmaceutical Ltd. plummeted over 10% in Hong Kong trading on Monday morning, after the Chinese drug maker announced a major licensing agreement that will require significant upfront payments.</p>\n\n<p>Sino Biopharm said one of its subsidiaries has signed an exclusive deal with YZY Biopharma to develop and commercialize the drug candidate M701 in mainland China. Under the terms of the deal, Sino Biopharm will pay around RMB315 million ($44 million) upfront to YZY.</p>\n\n<p>The company could also be on the hook for up to RMB700 million ($98 million) in additional milestone payments tied to future sales of the drug. Investors appeared to view the substantial upfront cash commitment as weighing on Sino Biopharm's near-term finances, sparking the sharp sell-off in the stock on Monday.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sino Biopharm Shares Plunge After Major Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sino Biopharm Shares Plunge After Major Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-08 17:48 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Sino Biopharmaceutical Ltd. plummeted over 10% in Hong Kong trading on Monday morning, after the Chinese drug maker announced a major licensing agreement that will require significant ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1187588565","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187588565","pubTimestamp":1728380930,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Sino Biopharmaceutical Ltd. plummeted over 10% in Hong Kong trading on Monday morning, after the Chinese drug maker announced a major licensing agreement that will require significant upfront payments.Sino Biopharm said one of its subsidiaries has signed an exclusive deal with YZY Biopharma to develop and commercialize the drug candidate M701 in mainland China. Under the terms of the deal, Sino Biopharm will pay around RMB315 million  upfront to YZY.The company could also be on the hoo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"股票轨迹中国生物制药股价在重大许可交易后暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"Shares of Sino Biopharmaceutical Ltd. plummeted over 10% in Hong Kong trading on Monday morning, after the Chinese drug maker announced a major licensing agreement that will require significant upfront payments.\nSino Biopharm said one of its subsidiaries has signed an exclusive deal with YZY Biopharma to develop and commercialize the drug candidate M701 in mainland China. Under the terms of the deal, Sino Biopharm will pay around RMB315 million ($44 million) upfront to YZY.\nThe company could also be on the hook for up to RMB700 million ($98 million) in additional milestone payments tied to future sales of the drug. Investors appeared to view the substantial upfront cash commitment as weighing on Sino Biopharm's near-term finances, sparking the sharp sell-off in the stock on Monday.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187588565"}